A 1-year prospective observational cohort study evaluating SARS-CoV-2-based vaccines as part of a National Vaccine Program
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs Ad26.COV2 S (Primary) ; AZD 1222 (Primary) ; Elasomeran (Primary) ; SARS-COV-2 vaccine-inactivated-Sinovac-Biotech (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- 03 Feb 2025 New trial record